Monitor Q4 2026 for ADVANCED-2 enrollment completion and THRIVE-3 interim data, these are the next major catalysts. The ADVANCED-3 redesign suggests a broader but potentially slower NMIBC strategy; watch for protocol details. Cash runway into 2028 provides a long development horizon but no near-term revenue inflection.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $3.91entry
- T+1 · 3mo ago −0.51%α −0.76% · $3.89
- T+5 · 3mo ago +1.79%α +2.19% · $3.98
- T+20 · 2mo ago −2.05%α −0.99% · $3.83
- T+60 · 13d ago −39.90%α −39.41% · $2.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Protara Therapeutics reported Q2 2026 net loss of $21.7M ($0.36/share), widening from a $15.0M loss in Q2 2025, driven by increased R&D spending. The company highlighted key pipeline milestones: expects to complete enrollment in the BCG-Unresponsive cohort of the ADVANCED-2 trial in Q4 2026, is redesigning the ADVANCED-3 trial as an exploratory study, and remains on track to report interim THRIVE-3 results in Q4 2026. Cash of $161.9M is expected to fund operations into 2028, but the widening losses and trial redesign signal a longer path to commercialization without near-term revenue catalysts.
Key Financial Metrics
Key Facts
- Q2 2026 net loss of $21.7M ($0.36/share) vs $15.0M ($0.35/share) in Q2 2025
- Cash and investments of $161.9M as of June 30, 2026, expected to fund operations into 2028
- Expects to complete enrollment in BCG-Unresponsive cohort of ADVANCED-2 trial in Q4 2026
- Redesigning ADVANCED-3 trial as multi-cohort exploratory study in broader NMIBC population
- On track to report interim THRIVE-3 results for IV Choline Chloride in Q4 2026
- Plans to submit BLA for TARA-002 in Lymphatic Malformations in 2H 2027
- R&D expenses increased to $17.0M from $10.8M year-over-year
Financial Impact
Net loss widened by $6.7M YoY to $21.7M; cash burn rate increased with R&D spend up 58%
Risk Factors
- Clinical trial delays or negative data from ADVANCED-2 or THRIVE-3
- Cash burn rate increasing faster than expected could require dilutive financing
- BLA submission for TARA-002 in LMs not expected until 2H 2027, limiting near-term catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342659 |
Track record
13 reports on TARA
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.50% at T+60 after the May 26, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
- Nov 6, 202610d ago 8-K Neutral 4/10 No price data
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $2.30 Now $2.38 +3.48% settles Feb 4
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 4/10 Viewing Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
- Jun 29, 202620w ago 8-K Neutral 2/10 Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
- May 26, 202625w ago EFFECT Bearish 5/10 Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
- May 15, 202626w ago Press Release Bullish 7/10 Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
- May 13, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers